Ascensión
López Díaz de Cerio
Profesional Investigadora
Centro de Investigación Médica Aplicada
Pamplona, EspañaPublications in collaboration with researchers from Centro de Investigación Médica Aplicada (32)
2024
-
Biomarkers of Efficacy and Safety of the Academic BCMA-CART ARI0002h for the Treatment of Refractory Multiple Myeloma
Clinical Cancer Research, Vol. 30, Núm. 10, pp. 2085-2096
-
Dendritic Cells in Cancer Immunology and Immunotherapy
Cancers, Vol. 16, Núm. 5
-
Molecular mechanisms promoting long-term cytopenia after BCMA CAR-T therapy in multiple myeloma
Blood Advances, Vol. 8, Núm. 21, pp. 5479-5492
-
Serum mass spectrometry for treatment monitoring in patients with multiple myeloma receiving ARI0002h CAR T-cells
British Journal of Haematology, Vol. 205, Núm. 4, pp. 1346-1355
2023
-
Fractionated initial infusion and booster dose of ARI0002h, a humanised, BCMA-directed CAR T-cell therapy, for patients with relapsed or refractory multiple myeloma (CARTBCMA-HCB-01): a single-arm, multicentre, academic pilot study
The Lancet Oncology, Vol. 24, Núm. 8, pp. 913-924
-
Optimization of universal allogeneic CAR-T cells combining CRISPR and transposon-based technologies for treatment of acute myeloid leukemia
Frontiers in Immunology, Vol. 14
2022
-
C5a elevation in convalescents from severe COVID-19 is not associated with early complement activation markers C3bBbP or C4d
Frontiers in Immunology, Vol. 13
-
CAR density influences antitumoral efficacy of BCMA CAR T cells and correlates with clinical outcome
Science Advances, Vol. 8, Núm. 39
2021
-
Idiotype vaccines produced with a non-cytopathic alphavirus self-amplifying RNA vector induce antitumor responses in a murine model of B-cell lymphoma
Scientific Reports, Vol. 11, Núm. 1
-
Immunologic characterization of COVID-19 patients with hematological cancer
Haematologica
-
Immunological Biomarkers of Fatal COVID-19: A Study of 868 Patients
Frontiers in Immunology, Vol. 12
-
Persistence of High Levels of Serum Complement C5a in Severe COVID-19 Cases After Hospital Discharge
Frontiers in Immunology, Vol. 12
-
Preclinical evaluation of a synthetic peptide vaccine against SARS-CoV-2 inducing multiepitopic and cross-reactive humoral neutralizing and cellular CD4 and CD8 responses
Emerging Microbes and Infections, Vol. 10, Núm. 1, pp. 1931-1946
2019
-
Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma
Nature Medicine, Vol. 25, Núm. 3, pp. 470-476
-
Tolerogenic dendritic cell-based treatment for multiple sclerosis (MS): A harmonised study protocol for two phase i clinical trials comparing intradermal and intranodal cell administration
BMJ Open, Vol. 9, Núm. 9
2018
-
A randomized phase II clinical trial of dendritic cell vaccination following complete resection of colon cancer liver metastasis 11 Medical and Health Sciences 1112 Oncology and Carcinogenesis
Journal for ImmunoTherapy of Cancer, Vol. 6, Núm. 1
-
Combined immunotherapy encompassing intratumoral poly-ICLC, dendritic-cell vaccination and radiotherapy in advanced cancer patients
Annals of Oncology, Vol. 29, Núm. 5, pp. 1312-1319
2017
-
Identification of LAG3 high affinity aptamers by HT-SELEX and Conserved Motif Accumulation (CMA)
PLoS ONE, Vol. 12, Núm. 9
-
Targeting NK-cell checkpoints for cancer immunotherapy
Current Opinion in Immunology, Vol. 45, pp. 73-81
2016
-
MRP1-CD28 bi-specific oligonucleotide aptamers: Target costimulation to drug-resistant melanoma cancer stem cells
Oncotarget, Vol. 7, Núm. 17, pp. 23182-23196